OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jun 2 2011OncoSec Medical Incorporated
OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.  

Dr. Adil Daud, a clinical trials adviser for Oncosec Medical, and Clinical Professor, Hematology/Oncology, University of California, San Francisco, will discuss trial results from a long-term, follow-up study of melanoma patients treated with DNA IL-12 delivered via electroporation.  Dr. Daud will lead the following poster session:

Session: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Discussion: "Systemic immune responses induced by intratumoral plasmid IL-12
electroporation in patients with melanoma"
Monday, June 6, 8:00 AM to 12:00 PM
Location: McCormick Place Hall A

Source:

OncoSec Medical Incorporated

Posted in: Device / Technology News | Medical Science News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Specific epigenetic pathway found to be involved in the development of melanoma drug resistance
Mediterranean diet and exercise reshape gut microbiome, aiding weight loss
Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance
Study suggests potential overdiagnosis of melanoma in white Americans
Second-generation melanoma vaccine prolongs survival of patients with skin cancer
Androgen receptor signaling found to upregulate gene driving melanoma severity in men
Study addresses knowledge gap of clinical features and outcomes of Black patients with melanoma
Increased stiffness in aging skin may contribute to higher rates of metastatic skin cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
UCLA and UAMS teams secure $3.2 million NIH grant for melanoma research